Austin, TX 11/1/2007 10:10:35 PM
Speak with other shareholders about: (OTCBB: CHDO), (NASDAQ: CISG) and (AMEX: ONI) .
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this CHDO news release, by
clicking this link: http://www.stockwire.com/CHDO
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CHDO
CHDT Corp. (OTCBB: CHDO) down 15% on 5.9 million shares traded.
CHDT Corp. (http://www.chdtcorp.com) is a holding company engaged through its operating subsidiaries in the following business lines: Capstone Industries, Inc. (www.capstoneindustries.com) is engaged in product development, manufacturing, distribution, logistics and product placement to importers, theme parks, and mass retail of souvenirs, gifts, and consumer products; and Overseas Building Supply (OBS) is engaged in distribution of building materials including but not limited to roof tiles, interior doors, and insulation materials. On Oct. 30th 2007, the company launched their STP(R) branded power tools and automotive accessories line at AAPEX, Las Vegas Sands Expo Center, Booth #940. "STP(R) is one of the most recognized brand names in the automotive industry with over 50 years of history and success behind it," said Reid Goldstein, President of Capstone Industries. "We have designed a spectrum of technologically innovative products that will enhance and complement the value of the STP(R) brand. STP(R) cordless power tools feature models with quick-charging Lithium Ion batteries and LED work-area lighting. Our STP(R) branded accessories include power inverters, jump starters, spotlights and garage clocks that are extremely automotive retail-friendly."
----------------------------------------------------------
Chat real-time with other investors about this CISG news release, by
clicking this link: http://www.stockwire.com/CISG
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CISG
CNinsure Inc. (NASDAQ: CISG) up 58% on 10.1 million shares traded.
Cninsure Inc. is a leading independent insurance agency and brokerage company operating in China. CNinsure's distribution network reaches some of China's most economically developed regions and affluent cities. The company distributes a wide variety of property and casualty and life insurance products underwritten by domestic and foreign insurance companies operating in China and provides insurance-related services. On Oct. 30th 2007, the company announced that its initial public offering of 11,762,413 American Depositary Shares ("ADSs"), each representing 20 ordinary shares of the company, was priced at an initial public offering price of $16.00 per ADS. The ADSs will begin trading on the Nasdaq Global Market on October 31, 2007 under the symbol "CISG."
----------------------------------------------------------
Chat real-time with other investors about this ONI news release, by
clicking this link: http://www.stockwire.com/ONI
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=ONI
Oragenics, Inc. (AMEX: ONI) up 84.3% on 297,000 shares traded.
Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. On Oct .31st 2007, the company announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the most recent submission of its Investigational New Drug Application (IND) for SMaRT Replacement Therapy(TM) had satisfactorily addressed all outstanding clinical hold issues, and that the company may now proceed with its second Phase 1 clinical trial. The study protocol is designed as an open label, single dose study for the evaluation of the safety and tolerability of the SMaRT(TM) replacement strain, A2JM, in healthy, adult male subjects, and includes an institutionalized phase during the clinical trial.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE RESEARCH GROUP INC..
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com, which is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares at any given time.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
